Since its inception, GENFIT continues to manage original R&D programs in task-sharing collaborations with pharmaceutical partners. GENFIT receives annual payments for such programs, and is eligible for milestone payments throughout the preclinical and clinical development period, as well as royalties upon product registration and commercialization.

In 2010, GENFIT continued its collaboration with SANOFI-AVENTIS through the SAVX1 program focused on Type 2 diabetes and vascular inflammation. During this program, numerous screening and compound profiling tools have been developed by GENFIT and then transferred to SANOFI-AVENTIS. A screening campaign on one of the program targets was completed in 2009 and resulted in the identification of active compounds eligible for milestone payments according to their development.

Today, through a new research contract signed with SANOFI-AVENTIS in the field of mitochondrial dysfunction and cardiometabolic disease, GENFIT’s historical collaboration with the pharmaceutical industry giant has taken on a new dimension via a significant risk-sharing aspect that highlights the strong commitment of both companies to this research area.

In parallel, GENFIT continues to work with the LABORATOIRES SERVIER on the research program SERX1, dedicated to the treatment of multiple factors of insulin resistance and Type 2 diabetes, and to the characterization and deorphanization of an innovative orphan nuclear receptor target. Significant progress has been made in this program, and was rewarded by successive milestone payments in 2009 and 2010.

Besides the above task-sharing partnerships, GENFIT also applies its know-how and technological platforms to customized service programs with more short-term payments.